About: Manejo farmacológico de pacientes con enfermedades hepáticas y pancreáticas que involucran terapias inmunosupresoras. Posicionamiento en el marco de la pandemia de SARS-COV-2 (COVID-19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Manejo farmacológico de pacientes con enfermedades hepáticas y pancreáticas que involucran terapias inmunosupresoras. Posicionamiento en el marco de la pandemia de SARS-COV-2 (COVID-19) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Manejo farmacológico de pacientes con enfermedades hepáticas y pancreáticas que involucran terapias inmunosupresoras. Posicionamiento en el marco de la pandemia de SARS-COV-2 (COVID-19)
Creator	Peláez-Luna, M Pérez-González, B García-Juárez, I González-Regueiro, J López-Díaz, F Miranda-Zazueta, G Moctezuma-Velázquez, C Uscanga-Domínguez, L
Source	Elsevier; Medline; PMC; WHO
abstract	Resumen La enfermedad por coronavirus 2019 (COVID-19) es causada por el virus de Síndrome Respiratorio Agudo Grave - Coronavirus 2 (SARS-CoV-2). COVID 19 ha afectado cerca de 2 millones de personas en todo el mundo en menos de 4 meses posterior al reporte de los primeros casos en China en diciembre 2019. La relación que guarda la enfermedad por SARS-Cov-2 con el tratamiento inmunosupresor utilizado en diversos trastornos gastrointestinales es incierta, esto genera el debate sobre suspender el tratamiento inmunosupresor para mejorar el pronóstico de la infección, lo cual incluye el riesgo inherente de rechazo de injerto o agudización de enfermedades autoinmunes que potencialmente pudieran agravar el curso de la infección. En base a la evidencia disponible se logra establecer una postura de tratamiento en pacientes con enfermedades gastrointestinales que requieren terapia inmunosupresora. Abstract The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus. COVID-19 affected close to 2 million persons worldwide in fewer than 4 months, after the report of the first cases in China in December 2019. The relation of the disease caused by SARS-Cov-2 to immunosuppressive treatment used in different gastrointestinal disorders is uncertain, resulting in debate with regard to suspending immunosuppressive therapy to improve infection outcome. Said suspension implies the inherent risk for graft rejection or autoimmune disease exacerbation that can potentially worsen the course of the infection. Based on the presently available evidence, a treatment stance has been established for patients with gastrointestinal diseases that require immunosuppressive therapy.
has issue date	2020-06-17(xsd:dateTime)
bibo:doi	10.1016/j.rgmx.2020.06.001
bibo:pmid	32620315
has license	els-covid
sha1sum (hex)	1bb5539ae937b404b75d16a5099dba54ddf2bb13
schema:url	https://doi.org/10.1016/j.rgmx.2020.06.001
resource representing a document's title	Manejo farmacológico de pacientes con enfermedades hepáticas y pancreáticas que involucran terapias inmunosupresoras. Posicionamiento en el marco de la pandemia de SARS-COV-2 (COVID-19)
has PubMed Central identifier	PMC7298481
has PubMed identifier	32620315
schema:publication	Rev Gastroenterol Mex
resource representing a document's body	covid:1bb5539ae937b404b75d16a5099dba54ddf2bb13#body_text
is schema:about of	named entity 'COVID-19' named entity 'QUE' named entity 'SARS-COV-2' named entity 'therapies' named entity 'pancreatic diseases' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'Pharmacologic' named entity 'igual' named entity 'SARS-Cov-2' named entity 'COVID-19' named entity 'mismo' named entity 'SARS-CoV-2' named entity 'peritonitis' named entity 'COVID-19' named entity 'como' named entity 'el momento' named entity 'COVID-19' named entity 'COVID-19' named entity 'el momento' named entity 'ECG' named entity 'COVID-19' named entity 'el debate' named entity 'Ciudad de México' named entity 'COVID-19' named entity 'pancreatitis' named entity 'COVID-19' named entity 'los mismos' named entity 'contienen' named entity 'pancreatitis' named entity 'COVID-19' named entity 'los mismos' named entity 'las guías' named entity 'pancreatitis' named entity 'off-label' named entity 'COVID-19' named entity 'COVID-19' named entity 'COVID-19' named entity 'COVID-19' named entity 'el mundo' named entity 'hasta ahora' named entity 'los tres' named entity 'decisiones' named entity 'COVID-19' named entity 'la respuesta' named entity 'COVID-19' named entity 'diabetes' named entity 'SARS-CoV-2' named entity 'esta' named entity 'esta' named entity 'COVID 19' named entity 'el momento' named entity 'si la' named entity 'hepatocarcinoma' named entity 'la toma' named entity 'el norte' named entity 'rituximab' named entity 'SARS-CoV-2' named entity 'puede ser' named entity 'rituximab' named entity 'COVID-19' named entity 'China' named entity 'mismo' named entity 'el efecto' named entity 'SARS-CoV-2' named entity 'SARS' named entity 'COVID-19' named entity 'COVID-19' named entity 'COVID-19' named entity 'el momento' named entity 'hacer' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'esta'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software